The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

  title={The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.},
  author={Isabella Pacchiarotti and David J Bond and Ross J. Baldessarini and Willem A. Nolen and Heinz Grunze and Rasmus W. Licht and Robert M. Post and Michael Berk and Guy M. Goodwin and Gary S. Sachs and Leonardo Tondo and Robert L. Findling and E. Youngstrom and Mauricio Tohen and Juan Undurraga and Ana M Gonz{\'a}lez-Pinto and Joseph F. Goldberg and Ayşeg{\"u}l Mavi Yıldız and Lori L. Altshuler and Joseph R. Calabrese and Philip B. Mitchell and Michael E. Thase and Athanasios Koukopoulos and Francesc Colom and Mark A. Frye and Gin S. Malhi and Konstantinos N. Fountoulakis and Gustavo H. V{\'a}zquez and Roy H. Perlis and Terence A. Ketter and Frederick Cassidy and Hagop Souren Akiskal and Jean Michel Azorin and Marc Valent{\'i} and D. Hidalgo Mazzei and Beny Lafer and Tadafumi Kato and Lorenzo Mazzarini and Anabel Mart{\'i}nez-Ar{\'a}n and Gordon Parker and Daniel Souery and Aysegul Ozerdem and Susan L. McElroy and Paolo Girardi and Michael Bauer and Lakshmi N. Yatham and Carlos A. Zarate and Andrew A. Nierenberg and Boris B. Birmaher and Shigenobu Kanba and Rif S El-Mallakh and Alessandro Serretti and Z{\'o}ltan Rihmer and Allan H. Young and Georgios Demetrios Kotzalidis and Glenda M. MacQueen and Charles L. Bowden and S. Nassir Ghaemi and Carlos L{\'o}pez-Jaramillo and Janusz K. Rybakowski and Kyooseob Ha and Giulio Perugi and Siegfried Kasper and Jay D. Amsterdam and Robert M. A. Hirschfeld and Fl{\'a}vio Kapczinski and Eduard Vieta},
  journal={The American journal of psychiatry},
  volume={170 11},
OBJECTIVE The risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence is lacking, expert consensus can guide treatment decisions. The International Society for Bipolar Disorders (ISBD) convened a task force to seek consensus recommendations on the use of antidepressants in bipolar disorders. METHOD An expert task force iteratively developed consensus through serial consensus-based revisions using the Delphi method. Initial survey items… 

Figures and Tables from this paper

The use of antidepressants in bipolar disorder patients with depression

The design features and results of studies dealing with depressive features and intervention strategies for bipolar disorders are summarized, focusing on pragmatic treatment decisions that clinicians can make to enhance the probability of both short and long term benefits for patients.

Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder

Patients in a depressive state had a significantly higher rate of antidepressant prescriptions than patients with other mental states, and patients who were prescribed antidepressants received fewer mood stabilizers, more anxiolytics, and more hypnotics than those who did not receive antidepressant prescriptions.

Antidepressants in bipolar depression: an enduring controversy

  • M. Gitlin
  • Psychology
    International Journal of Bipolar Disorders
  • 2018
A number of recent studies have demonstrated both the safety and efficacy of antidepressant monotherapy in treating bipolar II depression, and a subgroup of bipolar individuals need antidepressants in addition to mood stabilizers as part of an optimal maintenance treatment regimen.

Current landscape, unmet needs, and future directions for treatment of bipolar depression.

Are antidepressants mood destabilizers?

The Next Generation of Clinical Studies with Antidepressants in Bipolar Disorder

Only few trials with antidepressants in bipolar depression have systematically evaluated the potential clinical usefulness of biomarkers that may predict antidepressant response in BD and even less have thoroughly assessed the potential biological basis of switch risk.

Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder

The authors conclude that the real question is not whether ADs should or should not be used in bipolar depression, but which patients benefit from these drugs and which ones are impaired.

An overview of pharmacotherapy for bipolar I disorder

There is dire need for new, more targeted treatments in BD I, with a critical view of the side effects, as randomized controlled trials do not represent ‘real world’ patients and research efforts must also focus on treating cognitive deficits, which adds to lower functional outcome.

Antidepressant Treatment and Manic Switch in Bipolar I Disorder: A Clinical and Molecular Genetic Study

Investigation of the effects of individual genomics and antidepressant medication on the risk of manic switch in bipolar I disorder found that antidepressant medication and rs10262219 variants jointly increased the riskof manic switch after bipolar depression.



The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders.

Determination and dissemination of a consensus nomenclature serve as the first step toward producing a validated and standardized system to define course and outcome in bipolar disorders in order to identify predictors of outcome and effects of treatment.

New treatment guidelines for acute bipolar depression: a systematic review.

Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis.

Although antidepressants were found to be safe for the acute treatment of bipolar depression, their lack of efficacy may limit their clinical utility and further high-quality studies are required to address the existing limitations in the literature.

ECNP consensus meeting. Bipolar depression. Nice, March 2007

Risk factors for antidepressant-related switch to mania.

Bipolar patients with an earlier age at onset and an illness course characterized by lower rate of response to antidepressants and higher rate of switches into mania or hypomania were found to be the ones with higher switch risk.

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.

  • G. Goodwin
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2009
The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder, and are presented as recommendations to aid clinical decision making for practitioners: they may also serve as a source of information for patients and carers.

Effectiveness of adjunctive antidepressant treatment for bipolar depression.

The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch.

Overview of antidepressant treatment of bipolar depression.

Overall efficacy was significantly greater with antidepressants than with placebo-treatment and not less than was found in trials for unipolar major depression, and risks of non-spontaneous mood-switching specifically associated with antidepressant treatment are less than appears to be widely believed.

SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study.

International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression.

The scope of the discussions of the International Consensus Group extended to consider published evidence for the treatment of bipolar II depression and also special populations of patients with bipolar depression.